Decision On Moderna's COVID-19 Vaccine For Adolescents Delayed - What You Need To Know - Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

The FDA is delaying its decision to authorize Moderna Inc's MRNA COVID-19 vaccine for adolescents to assess the risk of a rare inflammatory heart condition, Wall Street Journal reported citing people familiar with the matter.
The agency has been inspecting the risk of myocarditis among younger men vaccinated with Moderna's shot, especially versus Pfizer Inc PFE and BioNTech SE's BNTX vaccine.
Related: After Sweden, Denmark Now Finland Stops Use of Moderna COVID-19 Jab In Young People: Report.
The agency has not yet determined whether there is heightened risk, and the delay could be several weeks, though the timing was unclear, the report said.
The agency plans to further review data before deciding whether to extend the vaccine's eligibility to younger people, the people said.
Moderna Chief Medical Officer Paul Burton said, "the FDA's data on vaccinations among 18- to 25-year-olds don't show any significant difference in the rate of myocarditis among people who took the Moderna or the Pfizer-BioNTech vaccines".
In June, Moderna filed for U.S. authorization of its vaccine among adolescents aged 12 through 17.
Related: EMA Says Heart Inflammation Likely Linked To mRNA-Based COVID-19 Vaccines.
Price Action: MRNA shares closed higher by 3.28% at $334.84 on Monday.